The Storm Prediction Center has introduced new severe weather outlook changes for the severe weather season starting in March. Here's what they changed.

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30% ...

Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million, bringing together two companies working on central nervous system therapies that have suffered ...

Sage is over the hump in its transition to a primary cloud-focused software company. which means operating margins should rise going forward as the benefits of scale kick in.